NetworkNewsBreaks – Check-Cap (NASDAQ: CHEK) Advances toward Regulatory Approval of Colonoscopy Alternative, C-Scan®
Check-Cap (NASDAQ: CHEK) is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the screening of precancerous polyps and cancer. The company’s C-Scan® system provides an alternative to the current Colorectal Cancer (CRC) screenings, such as a colonoscopy, to help increase screening rates. Unlike a colonoscopy, Check-Cap’s system doesn’t require a bowel prep, which is a huge selling point for at-risk patients. Check-Cap recently enrolled the first patient in its multi-center study of the C-Scan® system in support of its plans to submit for a CE Mark in the first…







